{"title":"The Central Role of Actin in Creutzfeldt-Jakob Disease: Unlocking Therapeutic Pathways.","authors":"Liliana Bastar-Juarez, Ximena Castillo-Estrada, Daniela Margarit-Mendez, Paola Coca-Gutierrez","doi":"10.1007/s12035-025-05112-z","DOIUrl":null,"url":null,"abstract":"<p><p>Creutzfeldt-Jakob disease (CJD) is a prion-caused condition characterized by progressive neurodegeneration and spongiform structural changes in the brain due to vacuolization and neuronal death. The disease is driven by the accumulation of abnormally folded prion proteins (PrPSc), derived from the normal cellular protein (PrPC). Actin, a fundamental protein essential for maintaining cellular structure and function, is critically involved in the pathophysiology of several neurodegenerative diseases, including Creutzfeldt-Jakob disease (CJD). In CJD, the dysregulation of actin-binding proteins such as cofilin and gelsolin significantly contributes to disease progression by disrupting actin turnover and cytoskeletal reorganization. The actin cytoskeleton is also essential for synaptic plasticity and the functionality of excitatory neurotransmitter receptors, such as glutamate-gated ion channels (AMPA) and N-methyl-D-aspartate (NMDA) receptors. As cytoskeletal integrity deteriorates, receptor dynamics become impaired, leading to disrupted calcium signaling and deficits in cognitive functions. Additionally, actin-based structures, known as tunneling nanotubes (TNTs), play crucial roles in prion spread by facilitating cell-to-cell transfer of prions. Simultaneously, the prion-infected neuronal environment promotes the formation of these structures, further driving disease progression. Targeting actin dynamics through the modulation of actin-binding proteins and related signaling pathways presents a promising avenue for therapeutic development. These approaches hold potential for addressing CJD for broader applications in neurodegenerative diseases characterized by cytoskeletal dysfunction. Current strategies focus on targeting cytoskeletal components such as microtubule stabilizers, actin-binding proteins, HDAC6 inhibitors, and small GTPases, further expanding the possibilities for effective treatments across various neurodegenerative conditions.</p>","PeriodicalId":18762,"journal":{"name":"Molecular Neurobiology","volume":" ","pages":"15132-15148"},"PeriodicalIF":4.3000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12035-025-05112-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Creutzfeldt-Jakob disease (CJD) is a prion-caused condition characterized by progressive neurodegeneration and spongiform structural changes in the brain due to vacuolization and neuronal death. The disease is driven by the accumulation of abnormally folded prion proteins (PrPSc), derived from the normal cellular protein (PrPC). Actin, a fundamental protein essential for maintaining cellular structure and function, is critically involved in the pathophysiology of several neurodegenerative diseases, including Creutzfeldt-Jakob disease (CJD). In CJD, the dysregulation of actin-binding proteins such as cofilin and gelsolin significantly contributes to disease progression by disrupting actin turnover and cytoskeletal reorganization. The actin cytoskeleton is also essential for synaptic plasticity and the functionality of excitatory neurotransmitter receptors, such as glutamate-gated ion channels (AMPA) and N-methyl-D-aspartate (NMDA) receptors. As cytoskeletal integrity deteriorates, receptor dynamics become impaired, leading to disrupted calcium signaling and deficits in cognitive functions. Additionally, actin-based structures, known as tunneling nanotubes (TNTs), play crucial roles in prion spread by facilitating cell-to-cell transfer of prions. Simultaneously, the prion-infected neuronal environment promotes the formation of these structures, further driving disease progression. Targeting actin dynamics through the modulation of actin-binding proteins and related signaling pathways presents a promising avenue for therapeutic development. These approaches hold potential for addressing CJD for broader applications in neurodegenerative diseases characterized by cytoskeletal dysfunction. Current strategies focus on targeting cytoskeletal components such as microtubule stabilizers, actin-binding proteins, HDAC6 inhibitors, and small GTPases, further expanding the possibilities for effective treatments across various neurodegenerative conditions.
克雅氏病(CJD)是一种由朊病毒引起的疾病,其特征是由于空泡化和神经元死亡导致的进行性神经变性和大脑海绵状结构改变。该疾病是由来自正常细胞蛋白(PrPC)的异常折叠朊病毒蛋白(PrPSc)的积累所驱动的。肌动蛋白是维持细胞结构和功能所必需的基本蛋白质,在包括克雅氏病(CJD)在内的几种神经退行性疾病的病理生理中起着关键作用。在CJD中,肌动蛋白结合蛋白(如cofilin和gelsolin)的失调通过破坏肌动蛋白周转和细胞骨架重组而显著促进疾病进展。肌动蛋白细胞骨架对于突触可塑性和兴奋性神经递质受体(如谷氨酸门控离子通道(AMPA)和n -甲基- d -天冬氨酸(NMDA)受体)的功能也是必不可少的。随着细胞骨架完整性的恶化,受体动力学受损,导致钙信号中断和认知功能缺陷。此外,以肌动蛋白为基础的结构,即隧道纳米管(TNTs),通过促进朊病毒在细胞间的转移,在朊病毒传播中起着至关重要的作用。同时,朊病毒感染的神经元环境促进这些结构的形成,进一步推动疾病进展。通过调节肌动蛋白结合蛋白和相关信号通路靶向肌动蛋白动力学为治疗发展提供了一条有希望的途径。这些方法在以细胞骨骼功能障碍为特征的神经退行性疾病中具有更广泛的应用潜力。目前的策略侧重于靶向细胞骨架成分,如微管稳定剂、肌动蛋白结合蛋白、HDAC6抑制剂和小gtpase,进一步扩大了有效治疗各种神经退行性疾病的可能性。
期刊介绍:
Molecular Neurobiology is an exciting journal for neuroscientists needing to stay in close touch with progress at the forefront of molecular brain research today. It is an especially important periodical for graduate students and "postdocs," specifically designed to synthesize and critically assess research trends for all neuroscientists hoping to stay active at the cutting edge of this dramatically developing area. This journal has proven to be crucial in departmental libraries, serving as essential reading for every committed neuroscientist who is striving to keep abreast of all rapid developments in a forefront field. Most recent significant advances in experimental and clinical neuroscience have been occurring at the molecular level. Until now, there has been no journal devoted to looking closely at this fragmented literature in a critical, coherent fashion. Each submission is thoroughly analyzed by scientists and clinicians internationally renowned for their special competence in the areas treated.